Lyell Immunopharma, Inc. (LYEL) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 43 days, typically, give or take 15 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Thu, Mar 12, 2026after close 71 8-K
Q3 FY2025Wed, Nov 12, 2025after close 43 8-K
Q2 FY2025Tue, Aug 12, 2025after close 43 8-K
Q1 FY2025Tue, May 13, 2025after close 43 8-K
Q4 FY2024Tue, Mar 11, 2025after close 70 8-K

What they guided beta

Q3 FY2026 "PiNACLE pivotal data disclosure is on track for mid-2027, with BLA submission expected to follow in the second half of 2027." exhibit
Q3 FY2026 "Completed technology transfer of LYL273 to the LyFE Manufacturing Center™ following FDA review of improved manufacturing process and updated analytical methods; additional clinical data and End-of-Phase 1 meeting with FDA expected in 2027." exhibit
Q3 FY2026 "Approximately $194.0 million in cash, cash equivalents and marketable securities as of September 30, 2026, together with net proceeds from the private placement, expected to fund operations into 2028." exhibit
Q3 FY2026 "With two pivotal trials underway, including our single-arm pivotal PiNACLE trial expected to complete enrollment by year end and on track for pivotal data and BLA submission in the second half of 2027, we are now focusing on preparation for commercialization." exhibit
Q3 FY2026 "Third Quarter Updates and Recent Business Highlights Rondecabtagene Autoleucel (ronde-cel): A next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to approved CD19‑targeted CAR T-cell therapies for the treatment of relapsed/refractory large B-cell lymphoma Ronde-cel is an autologous CAR T-cell product candidate under evaluation in two pivotal trials in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the third- or later-line (3L+) setting (PiNACLE) and the secon" exhibit
Q2 FY2026 "PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the second half of 2027" exhibit
Q2 FY2026 "Additional data from the U.S. Phase 1 trial of LYL273 in 3L+ patients with relapsed/refractory mCRC and End‑of-Phase 1 FDA meeting are expected in the second half of 2026" exhibit
Q2 FY2026 "Approximately $228.0 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to provide runway into Q3 2027 SOUTH SAN FRANCISCO, Calif., August 6, 2026 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer , today reported financial results and business highlights for the second quarter ended June 30, 2026." exhibit
Q2 FY2026 "Second Quarter Updates and Recent Business Highlights Rondecabtagene Autoleucel (Ronde-cel): A next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to approved CD19‑targeted CAR T-cell therapies for the treatment of large B-cell lymphoma (LBCL) Ronde-cel is an autologous CAR T-cell product candidate under evaluation in two pivotal trials in patients with relapsed/refractory (R/R) LBCL in the third- or later-line (3L+) setting (PiNACLE) and the second-line (2L) setting (PiNACLE‑H2H)." exhibit
Q2 FY2026 "Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in the second half of 2027." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/LYEL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/LYEL

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

LYEL earnings date badge

HTML

<a href="https://veritasdata.dev/company/LYEL/"><img src="https://veritasdata.dev/embed/LYEL.svg" alt="LYEL earnings date" width="240" height="56"></a>

Markdown

[![LYEL earnings date](https://veritasdata.dev/embed/LYEL.svg)](https://veritasdata.dev/company/LYEL/)

Script

<script async src="https://veritasdata.dev/embed/LYEL.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/LYEL"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.